Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nektar Therapeutics (NKTR – Research Report), Kymera Therapeutics (KYMR – Research Report) and PROCEPT BioRobotics (PRCT – Research Report).
Nektar Therapeutics (NKTR)
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Hold rating on Nektar Therapeutics, with a price target of $6.00. The company’s shares closed last Thursday at $3.56, close to its 52-week low of $2.96.
According to TipRanks.com, Goldstein is a 2-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Nektar Therapeutics with a $5.23 average price target.
See today’s best-performing stocks on TipRanks >>
Kymera Therapeutics (KYMR)
In a report released yesterday, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Kymera Therapeutics, with a price target of $93.00. The company’s shares closed last Thursday at $30.92.
According to TipRanks.com, Cann is a 1-star analyst with an average return of
Currently, the analyst consensus on Kymera Therapeutics is a Moderate Buy with an average price target of $61.67, implying a 108.8% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $47.00 price target.
PROCEPT BioRobotics (PRCT)
BTIG analyst Ryan Zimmerman maintained a Hold rating on PROCEPT BioRobotics yesterday. The company’s shares closed last Thursday at $44.00.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
PROCEPT BioRobotics has an analyst consensus of Moderate Buy, with a price target consensus of $53.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NKTR:
